cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Delayed NYSE 23:28:06 06/11/2026 HKT			5-day change	1st Jan Change
0.3929 ^USD	+1.26%		+2.67%	-70.90%

11-02	CbdMD, Inc. completed the acquisition of Operating assets and brands of Twinlab Consolidation Corporation.	CI
09-03	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-14

More transcripts

Analysts' recommendations: cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	US$0.3929	+1.26%	30,433
05/11/26	US$0.3880	-4.43%	65,075
04/11/26	US$0.4060	-3.10%	170,369
03/11/26	US$0.4190	+5.62%	273,835
02/11/26	US$0.3967	+3.66%	298,490

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.3880

Average target price

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - cbdMD, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - cbdMD, Inc.

Company calendar

Market Cap	4.35M 3.87M 3.54M 3.23M 6.08M 411M 6.25M 42.57M 17.02M 218M 16.32M 15.97M 687M	P/E 2026 *	-1.18x	P/E 2027 *	-2.04x
Enterprise Value	4.35M 3.87M 3.54M 3.23M 6.08M 411M 6.25M 42.57M 17.02M 218M 16.32M 15.97M 687M	EV / Sales 2026 *	0.2x	EV / Sales 2027 *	0.15x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

09-24	Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation	PR
09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-14	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-11	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR

1 day	+1.26%
1 week	+2.67%
Current month	+2.67%
1 month	-3.70%
3 months	-30.55%
6 months	-56.95%
Current year	-70.90%

1 week	0.37	0.46
1 month	0.33	0.46
Current year	0.33	1.34
1 year	0.33	2.56
3 years	0.33	13.84
5 years	0.33	727.2
10 years	0.33	2,606.4

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/4/26	Jeffrey Porter	Free	Director	1,572	0.0150%
14/4/26	William Raines	Free	Director	1,572	0.0150%
14/4/26	Bakari Sellers	Free	Director	1,572	0.0150%

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news: cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+1.26%	+2.67%	-49.63%	-93.08%	4.35M
ELI LILLY AND COMPANY	-0.18%	-3.91%	+45.31%	+128.86%	1,216B
JOHNSON & JOHNSON	+0.25%	-0.38%	+45.56%	+79.40%	656B
ABBVIE INC.	+0.38%	-2.02%	+31.91%	+104.63%	509B
ROCHE HOLDING AG	-0.89%	-3.92%	+46.15%	+63.44%	384B
MERCK & CO., INC.	-0.25%	-2.07%	+70.69%	+40.33%	362B
NOVARTIS AG	-0.97%	-0.61%	+30.46%	+57.83%	311B
ASTRAZENECA PLC	-0.86%	-0.34%	+8.40%	+35.38%	293B
AMGEN INC.	+0.18%	-1.08%	+46.07%	+68.96%	249B
GILEAD SCIENCES, INC.	+0.08%	-1.93%	+35.65%	+106.30%	208B
Average	-0.09%	+0.54%	+31.06%	+59.21%	418.78B
Weighted average by Cap.	-0.18%	+0.03%	+41.87%	+88.02%

	2026 *	2027 *
Net sales	21.92M 19.54M 17.87M 16.27M 30.67M 2.07B 31.5M 215M 85.84M 1.1B 82.29M 80.52M 3.46B	28.6M 25.48M 23.31M 21.23M 40.01M 2.7B 41.09M 280M 112M 1.43B 107M 105M 4.52B
Net income	-3.33M -2.97M -2.72M -2.47M -4.66M -315M -4.79M -32.63M -13.05M -167M -12.51M -12.24M -526M	-4.95M -4.41M -4.03M -3.67M -6.92M -467M -7.11M -48.43M -19.37M -248M -18.56M -18.17M -781M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time